Tarsus Pharmaceuticals, Inc.

Annual Trend FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Depreciation $37k $96k $312k $325k $744k $685k $855k
Amortization of intangible assets $0 $133k $540k $961k
Amortization/accretion of debt-related costs $0 $309k $385k $482k $593k
Net amortization/accretion on marketable securities $0 ($1.3m) ($3.2m) ($4.2m) ($5.5m)
Loss on debt extinguishment $255k $0 $0 $0 $1.9m $0
Realized/unrealized loss (gain) on equity investments $268k ($259k) $591k $0
Operating lease right-of-use asset obtained in exchange for operating lease liability $163k $726k $741k $0 $1.8m $384k $10.2m
Operating lease modification $0 $0 $1.1m $0
Net loss ($4.7m) ($26.8m) ($13.8m) ($62.1m) ($135.9m) ($115.6m) ($66.4m)
Stock-based compensation $18k $839k $8.5m $13.5m $19.8m $27.8m $41.7m
Non-cash lease expense $150k $294k $464k $541k $635k $682k
Change in fair value of equity warrants issued by licensee $76k $0 $987k $501k ($117k) $201k $0
Accounts receivable, net $0 ($16.6m) ($30.1m) ($38.3m)
Inventory $0 ($3.1m) ($2.0m) ($1.8m)
Other receivables ($32k) $16k ($73k) ($3.5m) $2.5m ($206k) ($754k)
Prepaid expenses ($2.0m) ($721k) ($2.9m) ($7.0m) $1.7m
Other non-current assets ($6k) ($75k) ($2.3m) ($215k) ($718k) $572k ($527k)
Accounts payable $245k $3.2m $3.9m $821k $13.2m $40.3m $6.9m
Accrued payroll and benefits $296k $741k $1.8m $2.7m $7.7m $2.6m $2.0m
Other accrued liabilities $8.7m $37.8m $45.4m
Other long-term liabilities $0 $115k ($67k) $185k ($233k) $0
Proceeds from sales and maturities of marketable securities $5.3m $174.8m $73.0m $361.8m
Purchases of marketable securities $0 ($149.4m) ($28.7m) ($262.6m) ($393.2m)
Intangible asset additions $0 ($4.0m) ($5.0m) $0
Purchases of property and equipment ($175k) ($456k) ($586k) ($506k) ($1.5m) ($1.6m) ($9.9m)
Proceeds from issuance of pre-funded warrants, net of paid issuance costs $0 $0 $9.4m $0
Proceeds from exercise of stock options $10k $103k $123k $592k $5.6m $6.3m
Additions of property and equipment included within accounts payable and other accrued liabilities $10k $34k $2k $21k $134k $99k $1.5m
Offering costs included within accounts payable $0 $0 $21k $0
Net cash used in operating activities ($3.7m) ($21.1m) $3.7m ($49.0m) ($117.5m) ($83.0m) ($12.5m)
Purchases of long-term investments $0 $0 ($3.0m) ($870k)
Net cash (used in) provided by investing activities ($175k) ($456k) ($586k) ($144.6m) $140.6m ($199.2m) ($42.1m)
Proceeds from long-term debt $20.0m $10.0m $75.0m $0
Payment of debt issuance costs $0 ($875k) $0 ($3.5m) $0
Payments for debt extinguishment $0 $0 ($31.9m) $0
Proceeds from issuance of common stock, net of paid issuance costs $74.4m $118.6m $98.3m $134.8m
Proceeds from sale of common stock under employee stock purchase plan $0 $221k $462k $985k $1.8m $2.3m
Net cash provided by financing activities $59.4m $131.8m $21k $94.0m $130.2m $154.7m $143.4m
Net increase (decrease) in cash, cash equivalents and restricted cash $55.6m $110.2m $3.2m ($99.7m) $153.3m ($127.6m) $88.8m
Cash, cash equivalents and restricted cash at beginning of period $58.0m $168.1m $171.3m $71.7m $224.9m $97.4m $186.2m
Interest expense paid in cash $0 $1.7m $2.9m $7.7m $8.3m